Drug and Medication Industry: Keio University – Developmental Therapeutics Review – Q4 2010

• Publication date: December 2010

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by G...

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Keio University - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Keio University human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Keio University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Keio University’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Keio University’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Keio University in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Keio University’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Keio University.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Keio University and identify potential opportunities in those areas.

Global Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Keio University Snapshot 5
Key Information 5
Key Facts 5
Keio University – Research and Development Overview 6
Key Therapeutic Areas 6
Keio University – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
Keio University – Pipeline Products Glance 12
Keio University Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 14
Keio University – Drug Profiles 15
Amrubicin 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CPT-11 + S-1 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Cyclophosphamide + Cytarabine + Radiation Therapy + Cord Blood Transplantation 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Granulocyte-Colony Stimulating Factor 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MAB Therapy 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MAB Therapy + Zoledronic Acid 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Pegylated Liposomal Doxorubicin + Carboplatin 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
TS-1 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
TS-1 + Gemcitabine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Urinastatin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Keio University – Pipeline Analysis 26
Keio University – Pipeline Products by Therapeutic Class 26
Keio University Pipeline Products By Target 28
Keio University – Pipeline Products by Route of Administration 30
Keio University – Pipeline Products by Molecule Type 31
Keio University - Dormant Projects 32
Keio University – Locations And Subsidiaries 33
Head Office 33
Financial Deals Landscape 33
Keio University, Deals Summary, 2004 to 2010 33
Keio University Detailed Deal Summary 34
Yamanouchi Pharmaceutical Enters Into Collaboration Agreement With Keio University 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 36
Contact Us 36
Disclaimer 36List of Tables
Keio University – Pipeline by Therapy Area and Indication, 2010 7
Keio University – Pipeline by Stage of Development, 2010 9
Keio University – Monotherapy Products in Pipeline, 2010 10
Keio University – Combination Treatment Modalities in Pipeline, 2010 11
Keio University - Phase II, 2010 12
Keio University - Phase I, 2010 14
Keio University - Pipeline By Therapeutic Class, 2010 26
Keio University - Pipeline By Target, 2010 28
Keio University – Pipeline By Route of Administration, 2010 30
Keio University – Pipeline By Molecule Type, 2010 31
Keio University - Dormant Developmental Projects, 2010 32
Keio University, Deals Summary, 2004 to 2010 33

List of Figures
Keio University – Pipeline by Therapy Area and Indication, 2010 7
Keio University – Pipeline by Stage of Development, 2010 9
Keio University – Monotherapy Products in Pipeline, 2010 10
Keio University – Combination Treatment Modalities in Pipeline, 2010 11
Keio University – Pipeline By Therapeutic Class, 2010 26
Keio University - Pipeline By Target, 2010 28
Keio University – Pipeline By Route of Administration, 2010 30
Keio University – Pipeline By Molecule Type, 2010 31